Greenwich LifeSciences (GLSI)’ Phase III clinical trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, is being expanded to Ireland. The company’s application to European regulators has been formally approved, adding Ireland as an approved country in FLAMINGO-01 in addition to Spain, France, Germany, Italy, Poland, Romania, and the US.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLSI: